ESH-iCMLf 16th International Conference Highlights in Chronic Myelogenous Leukemia

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: November 05, 2014
Expiration Date: November 05, 2015

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this educational activity, clinical experts discuss key findings relative to new and emerging treatments for chronic myelogenous leukemia (CML) from the ESH-iCMLf 16th International Conference on Chronic Myeloid Leukemia-Biology and Therapy. Each module will focus on the latest data, on what the data means in the clinical setting, and how clinicians may effectively incorporate this information to improve patient care, and ultimately, patient outcomes.

Target Audience

The target audience for this accredited activity is hematologists, oncologists, and associated multidisciplinary clinical specialists who provide care to patients with CML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Assess the latest data and research concerning treatment selection in CML, focusing on key elements of efficacy, side-effect management, and clinical trial limitations
  • Summarize new advances and approaches to monitoring for ongoing treatment efficacy and to improving patient adherence to medication regimens in CML
  • Outline new and emerging data concerning treatment resistance in CML, and in new therapeutic strategies for treating patients with the T315I mutation
  • Recognize specific clinical unmet needs of CML patients and trials seeking to address those needs, such as those seeking reliable tests which can differentiate between patients that can safely discontinue therapy from those who must continue therapy
  • Propose appropriate changes in practice based on clinical trial findings


The Role of Monitoring in Patients Who Are Not Responding Adequately to Tyrosine Kinase Inhibitor Therapy − Timothy P. Hughes, MD

What Has Just Happened to the Safety of TKIs? – Michael J. Mauro, MD

The Impact of Ponatinib Dose Intensity on Selected Adverse Events − Michael J. Mauro, MD

Alternative Therapies in CML: What Can We Target When BCR-ABL Is Not Sufficient?– Danilo Perrotti, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through November 5, 2015. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Timothy P. Hughes, MD
Clinical Professor
Department of Medicine
Department of Haematology
Centre for Cancer Biology
Adelaide, Australia

Dr. Timothy Hughes received his medical training at The University of New South Wales, Australia and is a clinical professor in the Department of Medicine at the University of Adelaide, Australia. He is also head of the Department of Haematology in SA Pathology and the Centre for Cancer Biology, Adelaide.

Dr. Hughes is a fellow of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australia. He is a member of the Haematology Society of Australia and New Zealand, and the Australasian Leukaemia and Lymphoma Group (ALLG). In addition, Dr. Hughes is the principal investigator in the Australasian Leukaemia and Lymphoma Group (ALLG) trial in de novo chronic myeloid leukemia (CML) patients with selective intensification of imatinib. He has published over 100 articles in peer-reviewed journals and his major field of interest is the molecular monitoring of response in leukemia and the mechanisms of drug resistance.

Michael J. Mauro, MD
Professor of Medicine
Leader, Myeloproliferative Neoplasms Program
Leukemia Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Dr. Michael Mauro received his medical degree from Dartmouth Medical School and completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan. He is professor of medicine and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Mauro has practiced as a board-certified hematologist for the past 15 years. Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13 years. There he directed the chronic myeloid leukemia (CML) clinical trial program and was involved in the early development and sentinel clinical studies of targeted therapy for CML.

Dr. Mauro’s clinical expertise is in treating patients with CML as well as other myeloproliferative disorders including myelofibrosis, polycythemia, and thrombocytosis, as well as less common conditions such as eosinophilic and mast cell disorders. His research interests include optimizing therapy response in CML, late and emerging side effects of kinase inhibitors, and decision-making amongst therapies for CML and other myeloproliferative neoplasms. Dr. Mauro’s patient care philosophy is to offer in-depth explanation regarding diagnoses and to engage in active partnership with his patients and their referring providers to personalize recommendations and monitoring given the chronic nature of the disorders he treats.

Danilo Perrotti, MD, PhD
Director, Basic Hematologic Research
The Greenebaum Cancer Center
University of Maryland
Baltimore, Maryland

Dr. Danilo Perrotti received his medical degree from the University of Rome "La Sapienza" Italy, and his PhD in biotechnology from the University of L'Aquila, Italy. He continued training as a research assistant in the Molecular Oncogenesis Lab at Regina Elena Cancer Institute of Rome, Italy, and as a postdoctoral researcher at Kimmel Cancer Institute, Thomas Jefferson University in Philadelphia. Dr. Perrotti is a tenured professor in the Department of Medicine and Department of Biochemistry and Molecular Biology at the University of Maryland School of Medicine. He is director of basic hematologic research of the Greenebaum Cancer Center, University of Maryland, Baltimore. In addition he is an honorary senior lecturer (visiting faculty) at Hammersmith Hospital, Division of Haematology, The Imperial College of London.

Dr. Perrotti is certified by the Italian Medical Board Examination. He holds professional memberships in the American Association for Cancer Research (AACR), American Society for Cell Biology (ASCB), American Association for the Advancement of Science (AAAS), American Society of Hematology (ASH), and the Alliance former Cancer and Leukemia Group B (CALGB). Dr. Perrotti is a reviewer for Medical Science Monitor Journal and Frontiers in Cancer Molecular Targets and Therapeutics, and is on the editorial board of The Open Cell Signaling Journal, Cell Death & Disease.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-14-034-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour(s). Program Number: 14-034-356


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Timothy Hughes has received honoraria related to formal advisory activities and grant support related to research activities from ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb, and Novartis AG.

Dr. Michael Mauro has received honoraria as a consultant from ARIAD Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Novartis AG, and Pfizer Inc.

Dr. Danilo Perrotti has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Drs. Hughes, Mauro, and Perrotti have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. Hughes, Mauro, and Perrotti have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from ARIAD Pharmaceuticals, Inc., Novartis, and Teva Pharmaceuticals.

©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.